MedTrace Logo

Second Study of the Effect of Teriparatide on Hip Fracture Healing

NCT01473602 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2015-04-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age with a recent hip (femoral neck) fracture caused by low-trauma (for example, fall from standing height or less).

Conditions

  • Femur Neck Fracture

Interventions

DRUG

Teriparatide

Administered by SC injection

DRUG

Placebo

Administered by SC injection

DIETARY_SUPPLEMENT

Calcium supplementation

Administered orally

DIETARY_SUPPLEMENT

Vitamin D supplementation

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States
  • Belgium
  • Croatia
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Netherlands
  • Poland
  • Romania
  • South Korea
  • Switzerland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01473602 on ClinicalTrials.gov